tiprankstipranks
Trending News
More News >
Innate Pharma SA (FR:IPH)
:IPH
France Market

Innate Pharma SA (IPH) Stock Forecast & Price Target

Compare
10 Followers
See the Price Targets and Ratings of:

IPH Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Innate
Pharma SA
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IPH Stock 12 Month Forecast

There Are No Analyst Ratings for FR:IPH In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

IPH Financial Forecast

IPH Earnings Forecast

Next quarter’s earnings estimate for IPH is -€0.12 with a range of -€0.12 to -€0.12. The previous quarter’s EPS was -€0.25. IPH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year IPH has Performed in-line its overall industry.
Next quarter’s earnings estimate for IPH is -€0.12 with a range of -€0.12 to -€0.12. The previous quarter’s EPS was -€0.25. IPH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year IPH has Performed in-line its overall industry.

IPH Sales Forecast

Next quarter’s sales forecast for IPH is €2.15M with a range of €2.15M to €2.15M. The previous quarter’s sales results were €1.67M. IPH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year IPH has Performed in-line its overall industry.
Next quarter’s sales forecast for IPH is €2.15M with a range of €2.15M to €2.15M. The previous quarter’s sales results were €1.67M. IPH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year IPH has Performed in-line its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on FR:IPH
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
€2.49€2.23
Hold
37.65%
Upside
Reiterated
10/07/25
Goldman Sachs Sticks to Their Hold Rating for Innate Pharma SA (IPHYF)
Kepler Capital  Analyst forecast on FR:IPH
Kepler Capital
Kepler Capital
€3.1
Hold
91.36%
Upside
Reiterated
05/23/25
Innate Pharma SA (IPHYF) Receives a Hold from Kepler Capital
Stifel Nicolaus Analyst forecast on FR:IPH
Stifel Nicolaus
Stifel Nicolaus
€5.7
Buy
251.85%
Upside
Reiterated
02/17/25
Buy Rating for Innate Pharma: Lacutamab's Breakthrough Designation and Market Potential Drive Positive Outlook
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on FR:IPH
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
€2.49€2.23
Hold
37.65%
Upside
Reiterated
10/07/25
Goldman Sachs Sticks to Their Hold Rating for Innate Pharma SA (IPHYF)
Kepler Capital  Analyst forecast on FR:IPH
Kepler Capital
Kepler Capital
€3.1
Hold
91.36%
Upside
Reiterated
05/23/25
Innate Pharma SA (IPHYF) Receives a Hold from Kepler Capital
Stifel Nicolaus Analyst forecast on FR:IPH
Stifel Nicolaus
Stifel Nicolaus
€5.7
Buy
251.85%
Upside
Reiterated
02/17/25
Buy Rating for Innate Pharma: Lacutamab's Breakthrough Designation and Market Potential Drive Positive Outlook
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Innate Pharma SA

3 Months
xxx
Success Rate
1/4 ratings generated profit
25%
Average Return
-14.20%
reiterated a xxx
rating 12 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 25.00% of your transactions generating a profit, with an average return of -14.20% per trade.
1 Year
Eric Le BerrigaudStifel Nicolaus
Success Rate
1/4 ratings generated profit
25%
Average Return
-6.75%
reiterated a buy rating 12 months ago
Copying Eric Le Berrigaud's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -6.75% per trade.
2 Years
xxx
Success Rate
1/4 ratings generated profit
25%
Average Return
-19.38%
reiterated a xxx
rating 12 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of -19.38% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IPH Analyst Recommendation Trends

Rating
Apr 25
May 25
Oct 25
Nov 25
Jan 26
Strong Buy
0
0
0
0
0
Buy
0
0
0
0
0
Hold
3
4
34
51
62
Sell
0
0
1
1
1
Strong Sell
0
0
0
0
0
total
3
4
35
52
63
In the current month, IPH has received 0 Buy Ratings, 62 Hold Ratings, and 1 Sell Ratings. IPH average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

IPH Stock Forecast FAQ

What is FR:IPH’s average 12-month price target, according to analysts?
Currently, no data Available
What is FR:IPH’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for FR:IPH, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is Innate Pharma SA a Buy, Sell or Hold?
      Currently, no data Available
      What is Innate Pharma SA’s share price target?
      Currently, no data Available
      What do analysts say about Innate Pharma SA?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of Innate Pharma SA?
      To buy shares of FR:IPH, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.